

INTRODUCTION	XXII
STUDY GOAL AND OBJECTIVES	XXII
REASONS FOR DOING THE STUDY	XXII
CONTRIBUTIONS OF THE STUDY AND FOR WHOM.....	XXIII
SCOPE AND FORMAT	XXIII
METHODOLOGY	XXIV
INFORMATION SOURCES.....	XXIV
ANALYST'S CREDENTIALS.....	XXIV
RELATED BCC WORK CREDENTIALS, INCLUDING WORK DONE BY OTHER AUTHORS	XXIV
BCC ON-LINE SERVICES.....	XXV
DISCLAIMER	XXVI
 SUMMARY.....	 XXVII
SUMMARY TABLE MARKETS FOR 'NEW ANTIBIOTICS,' AND HIV/AIDS DRUGS BY CATEGORY, WORLDWIDE, THROUGH 2009 (\$ MILLIONS)	XXVII
SUMMARY FIGURE MARKETS FOR 'NEW ANTIBIOTICS,' AND HIV/AIDS DRUGS BY CATEGORY, WORLDWIDE, 2001-2009 (\$ MILLIONS).....	XXVIII
 OVERVIEW	 1
A BRIEF HISTORY OF BUGS AND MAN.....	1
TRENDS IN MORTALITY FROM INFECTIOUS DISEASES	1
TABLE 1 TRENDS IN MORTALITY FROM INFECTIOUS DISEASES: 1900-1990.....	2
Spanish Influenza Pandemic	2
PATHOGENIC MICROBES AND INFECTIOUS DISEASES RECOGNIZED BETWEEN 1973 AND 1997.....	2
TABLE 2 DISEASE-CAUSING BACTERIA, PARASITES AND VIRUSES IDENTIFIED SINCE 1973.....	3
TABLE 2 (CONTINUED)	4
SETTING THE STAGE FOR PANDEMIC INFECTIOUS DISEASES	4
THE RAPID EVOLUTION OF MICROBES.....	4
A PARADIGM FOR A NEW PANDEMIC	5
CURRENT TECHNOLOGIES FOR ADDRESSING POTENTIAL PANDEMIC THREATS.....	5
TABLE 3 TECHNOLOGIES TO ADDRESS POTENTIAL PANDEMIC THREATS	6
 THE NEW ANTIBIOTIC MARKET	 7
THE GREATEST CHALLENGE FACING THE ANTI-INFECTIVE DRUG MARKET—DRUG RESISTANCE	7
THE CRISIS OF ANTIBIOTIC RESISTANCE	8
The Microbiology of Bacterial Resistance.....	9
Mechanisms of Resistance.....	9

Beta-Lactamase Production	9
Importing Resistance Genes from Other Organisms	10
Alteration of Binding Sites to Circumvent Anti- Infective Effectiveness.....	11
Antibiotic Efflux.....	12
GEOGRAPHIC SNAPSHOT OF RESISTANCE	12
THE PRIMARY REASONS FOR THE DEVELOPMENT OF ANTIBIOTIC RESISTANCE.....	13
Broad Spectrum Prescriptions	13
Patient Pressure	13
Healthcare Policy.....	14
INTERNATIONAL EFFORTS TO ADDRESS MICROBIAL RESISTANCE	14
Efforts by the World Health Organization	15
Efforts by the U.S. Congress	15
Strategies Implemented In The United Kingdom.....	16
NO ADVOCATES FOR MULTIDRUG-RESISTANT BACTERIAL DISEASES.....	17
THE IMPACT OF THINNING PIPELINES	17
THE IMPACT OF THINNING PIPELINES (CONTINUED)	18
THE EFFECT OF DRUG SHORTAGES	19
THE ROLE OF COUNTERFEIT DRUGS	19
INSURERS GET INVOLVED	19
RESISTANCE BY CLASS OF ANTIBIOTIC	20
FLUOROQUINOLONES	20
MRSA Correlation	20
Expanded-spectrum Fluoroquinolones	21
Median MIC ₉₀ Values of Gram-Negative Organisms to Selected Fluoroquinolones	22
<i>TABLE 4 MEDIAN MIC₉₀ (MICROGRAM/ML) VALUES OF GRAM-NEGATIVE ORGANISMS TO SELECTED MARKETED AND DEVELOPMENT-STAGE FLUOROQUINOLONES</i>	<i>22</i>
<i>TABLE 5 MEDIAN MIC₉₀ (MICROGRAM/ML) VALUES OF GRAM-POSITIVE ORGANISMS TO SELECTED MARKETED AND DEVELOPMENT-STAGE FLUOROQUINOLONES</i>	<i>23</i>
MACROLIDES	23
Prescription Use in Selected Countries	24
<i>TABLE 6 ANNUAL MACROLIDE PRESCRIPTIONS PER 1,000 INHABITANTS IN SIX COUNTRIES IN 1980 AND 1990.....</i>	<i>24</i>
Antibiotic Use and Rate of Macrolide-Resistant <i>Streptococcus Pneumoniae</i> in Selected Countries.....	24
<i>TABLE 7 TOTAL MACROLIDE USE AND RATE OF MACROLIDE-RESISTANT S. PNEUMONIAE IN SELECTED COUNTRIES.....</i>	<i>24</i>

Antibiotic Use and the Rate of Macrolide-Resistant <i>Streptococcus Pyogenes</i> in Selected Countries	25
TABLE 8 TOTAL MACROLIDE USE AND RATE OF MACROLIDE-RESISTANT <i>S.</i> <i>PYOGENES</i> IN SELECTED COUNTRIES	25
PENICILLINS	26
TABLE 9 ANNUAL BETA-LACTAM PRESCRIPTIONS PER 1,000 INHABITANTS IN SIX COUNTRIES IN 1980 AND 1990	26
TABLE 10 TOTAL ANTIBIOTIC USE AND RATE OF PENICILLIN- NONSUSCEPTIBLE <i>S. PNEUMONIAE</i> IN SELECTED COUNTRIES.....	26
TABLE 10 (CONTINUED)	27
SELECTED OTHER AGENTS.....	27
TABLE 11 PERCENT RESISTANCE TO CEFTAZIDIME, CIPROFLOXACIN, IMIPENEM AND PIPERACILLIN IN <i>P. AERUGINOSA</i> ISOLATES FROM BLOOD: SAN FRANCISCO COUNTY, CALIFORNIA, 1996-1999 (%).....	28
THE LEADING DRUG-RESISTANT BACTERIA	28
HOSPITAL AND COMMUNITY-ACQUIRED BACTERIAL PATHOGENS IN THE U.S.	29
TABLE 12 ANNUAL INCIDENCE OF INFECTIONS CAUSED BY HOSPITAL- AND COMMUNITY-ACQUIRED BACTERIAL PATHOGENS: U.S.....	29
DISEASE INCIDENCE BY BACTERIAL PATHOGEN IN U.S.....	29
TABLE 13 DISEASE INCIDENCE BY BACTERIAL PATHOGEN (U.S.).....	30
Selected Resistant Bacteria	30
TABLE 14 SELECTED ORGANISMS AND AGENTS TO WHICH THEY HAVE DEVELOPED RESISTANCE	30
TABLE 14 (CONTINUED)	31
ENTEROCOCCAL INFECTIONS.....	31
Vancomycin Resistance	31
Variant Esp Gene Vancomycin-susceptible <i>E.</i> <i>faecium</i>	32
Biofilm-Formation Capacity.....	32
Ampicillin Resistance	33
TABLE 15 RESISTANCE PATTERNS AMONG ENTEROCOCCAL ORGANISMS ISOLATED FROM BLOODSTREAM INFECTIONS.....	34
<i>ESCHERICHIA COLI</i>	34
<i>HELICOBACTER PYLORI</i>	35
<i>HEMOPHILUS INFLUENZAE</i>	36
<i>KLEBSIELLA PNEUMONIAE</i>	36
PNEUMOCOCCUS	36
<i>PSEUDOMONAS AERUGINOSA</i>	37
TABLE 16 IN VITRO SUSCEPTIBILITY OF <i>P. AERUGINOSA</i> ISOLATES FROM PATIENTS WITH LOWER RESPIRATORY TRACT INFECTIONS.....	37
<i>STAPHYLOCOCCUS AUREUS</i>	37
MRSA	38
Community-acquired MRSA	38

Nursing Homes	39
Intensive Care Units and Medical Devices.....	39
Vancomycin Resistance	39
STREPTOCOCCAL INFECTIONS	40
<i>Streptococcus Pneumoniae</i>	40
Penicillin and Other Drug Resistances.....	40
Geographic Specificity	41
Cephalosporin Resistance	42
TABLE 17 COMPARISON OF PERCENT OF STREPTOCOCCUS PNEUMONIAE ISOLATES NONSUSCEPTIBLE TO THIRD-GENERATION CEPHALOSPORINS BY SITE: ANTIBIOGRAMS VERSUS ABCs	42
Erythromycin Resistance	42
TABLE 18 COMPARISON OF PERCENT OF STREPTOCOCCUS PNEUMONIAE ISOLATES NONSUSCEPTIBLE TO ERYTHROMYCIN BY SITE: ANTIBIOGRAMS VERSUS ABCs.....	42
Penicillin Resistance	43
TABLE 19 COMPARISON OF PERCENT OF STREPTOCOCCUS PNEUMONIAE ISOLATES NONSUSCEPTIBLE TO PENICILLIN BY SITE: ANTIBIOGRAMS VERSUS ABCs.....	43
Serotype 3.....	43
New Developments	44
FOODBORNE PATHOGENS.....	44
DRUG RESISTANCE IN SELECTED DISEASES	45
DYSENTERY.....	45
PNEUMONIA.....	46
Leading Causes.....	46
TABLE 20 FREQUENCY OF OCCURRENCE OF BACTERIAL PATHOGENS IMPLICATED IN PNEUMONIA IN HOSPITALIZED PATIENTS, US.....	46
Bacterial Versus Viral Infections.....	47
Penicillin-Resistant Cases in Selected Countries	47
TABLE 21 PERCENTAGE OF HOSPITALIZED PATIENTS IN SELECTED COUNTRIES INFECTED WITH PENICILLIN-RESISTANT PNEUMOCOCCI.....	47
Demand for Broad-spectrum Drugs.....	48
Community-acquired Pneumonia	48
SALMONELLA INFECTION	48
TUBERCULOSIS	48
Tuberculosis (Continued)	49
The WHO's Global Project on Anti-tuberculosis Drug Resistance Surveillance	50
Geographic Specificity	50
TABLE 22 PERCENTAGE OF DRUG-RESISTANT STRAINS AMONG NEW CASES OF TUBERCULOSIS IN SELECTED COUNTRIES, 2000.....	51
Geographic Specificity (Continued)	52
2004 Update on the Problem of MDR Tuberculosis	53

Applying Effective Treatment	53
The DOTS Plan	54
Developing Effective Diagnostics for Detection of MDR	
Tuberculosis.....	55
Current Methods.....	55
STRATEGIES TO COMBAT BACTERIAL RESISTANCE IN THE	
HOSPITAL SETTING	56
DEVELOPMENT OF NARROW-SPECTRUM AGENTS.....	56
AVOIDANCE OF UNDERDOSING	56
ROTATING ANTIBIOTIC AGENTS.....	56
SURGICAL PROPHYLAXIS	57
ANTIBIOGRAMS	57
THE IDEAL ANTIBIOTIC	58
THE RELATIONSHIP OF DRUG RESISTANCE TO THE USE OF	
ANTIBIOTICS IN AGRICULTURE	58
FACTORS CONTRIBUTING TO OVERUSE OF	
ANTIMICROBIALS IN FOOD ANIMALS	59
SCREENING FOR ANTIBIOTICS IN FOOD ANIMAL	
PRODUCTS.....	60
DRUG-RESISTANT BACTERIA IN LIVESTOCK.....	60
Fluoroquinolone Resistance	61
Vancomycin Resistance	61
Avoparcin	61
Aquaculture	62
Government Regulation	62
GLOBAL EFFORTS TO ADDRESS ANTIMICROBIAL USAGE	
IN AGRICULTURE	62
MICROBES IN LIVESTOCK MANURE	63
TECHNOLOGICAL STRATEGIES TO COMBAT RESISTANCE.....	63
EFFLUX PUMP INHIBITORS.....	64
Mechanism.....	65
Efficacy.....	66
Research.....	66
Adverse Effects	66
PRIONS	67
QUORUM SENSING	67
Quorum Sensing (Continued).....	68
SEQUENCING OF BACTERIAL GENOMES.....	69
THE MARKET FOR SELECTED 'NEW ANTIBIOTIC' PRODUCTS.....	70
<i>TABLE 23 WORLDWIDE SALES AND YEAR OF FDA APPROVAL OF SELECTED</i>	
<i>NEW ANTIBIOTIC' PRODUCTS, THROUGH 2009 (\$ MILLIONS)</i>	<i>70</i>

<i>TABLE 24 THE MARKETS FOR SELECTED NEW ANTIBIOTICS AND EXISTING ANTIBIOTICS, BY CATEGORY: WORLDWIDE SALES, THROUGH 2009 (\$ MILLIONS)</i>	71
<i>FIGURE 1 THE MARKETS FOR SELECTED NEW ANTIBIOTICS AND EXISTING ANTIBIOTICS, BY CATEGORY: WORLDWIDE SALES, 2001-2009 (\$ MILLIONS)</i>	71
MARKET SHARE BY COMPANY FOR NEW ANTIBIOTICS	72
<i>FIGURE 2 MARKET SHARE BY COMPANY FOR NEW ANTIBIOTICS: 2004 AND 2009 (%)</i>	72
PRODUCTS TARGETED AT ANTIBIOTIC RESISTANCE	73
PRODUCTS INTRODUCED IN 2001, 2002 AND 2003	73
<i>TABLE 25 ANTIBACTERIAL PRODUCT APPROVALS, U.S.: 2001-2003</i>	73
<i>TABLE 25 (CONTINUED)</i>	74
<i>TABLE 25 (CONTINUED)</i>	75
SELECTED PRODUCTS APPROVED IN 2001, 2002 AND 2003	75
Cubicin	75
Mechanism	76
Indications.....	76
Market.....	77
Factive.....	77
Invanz	78
Levaquin	79
Spectracef.....	79
Tequin	80
Vigamox	81
Zithromax.....	81
Mechanism and Efficacy.....	81
Market.....	82
Zithromax Single Dose, Tri-Pak and IVVial-Mate.....	82
Zosyn	83
Zymar	83
Zyvox	84
SELECTED PRODUCTS PROJECTED TO BE INTRODUCED IN 2004 AND 2005	84
<i>TABLE 26 PROJECTED ANTIBACTERIAL PRODUCT APPROVALS, U.S.: 2004-2005</i>	85
<i>TABLE 26 (CONTINUED)</i>	86
<i>TABLE 26 (CONTINUED)</i>	87
<i>TABLE 26 (CONTINUED)</i>	88
ABT-773	88
Augmentin XR	89
CholeraGarde.....	89
Cubicin	89
Dalbavancin	90
Doripenem.....	90

Faropenem	91
Floxin Otic.....	91
Gracevit.....	92
Helicide	92
Iclaprim.....	93
ISV-401.....	93
Ketek	93
Ketek (Continued).....	94
MBI-226	95
Merrem I.V.....	96
Oritavancin	96
Ramoplanin.....	97
Rifaximin.....	98
Segard	99
StaphVAX	100
Tifacogin.....	100
Tigecycline	101
Zithromax.....	102

SELECTED PROMISING PRODUCTS IN EARLIER STAGES

OF DEVELOPMENT	103
AltaStaph	103
Glycodendriprotein	104
Isegaran.....	105
Lysostaphin.....	106
Oligosaccharides	106
Oxazolidinones.....	107
Zyvox.....	107
Streptogramins	108
Synercid.....	108
Synercid (Continued)	109

INNOVATIVE TECHNOLOGIES IN EARLY RESEARCH..... 110

ANTIBIOTIC-PRODUCING BACTERIA

BACTERIOPHAGES..... 110

Bacteriophages (Continued)..... 111

Q Beta

NATURAL PROTECTIVE MECHANISMS OF BACTERIA

Natural Protective Mechanisms of Bacteria (Continued)..... 113

NUBIOTICS

PEPTIDE DRUGS..... 115

Peptide Deformylase Inhibitors

VIRAL PANDEMIC THREATS	116
WHAT IS A VIRUS?	116
THE VIRAL PANDEMIC OF 2004—HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)	116
THE VIRAL PANDEMIC OF 2004.. (CONTINUED).....	117
TRANSMISSION OF HIV	118
EARLY SYMPTOMS AND PROGRESS OF HIV INFECTION.....	118
THE EXPANDED DEFINITION OF AIDS	118
THE PANDEMIC	119
HIV and AIDS in Africa—A Timeline of Death	120
Leading Causes of Death.....	121
TABLE 27 LEADING CAUSES OF DEATH IN AFRICA: 2000.....	121
Life Expectancy.....	121
TABLE 28 LIFE EXPECTANCY IN SELECTED AFRICAN COUNTRIES: 1950-2000.....	121
TABLE 28 (CONTINUED)	122
HIV and AIDS in the Ex-Soviet Bloc—An Africa in the Making?	122
MATHEMATICAL MODELS FOR THE AIDS EPIDEMIC	123
Mathematical Models for the Aids Epidemic (Continued).....	124
HIV AND AIDS STATISTICS	125
Number of HIV/Living with AIDS Cases in 2003 by Geographic Region	126
TABLE 29 ESTIMATED NUMBER OF PERSONS INFECTED WITH HIV/LIVING WITH AIDS, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION: 2003.....	126
Geographic Region 2003 Percentage of Global HIV Cases by Geographic Region.....	126
TABLE 30 PERCENT OF GLOBAL HIV CASES BY GEOGRAPHIC REGION: 2003.....	126
New HIV Cases in 2003 by Region	127
TABLE 31 ESTIMATED NUMBER OF PEOPLE NEWLY INFECTED WITH HIV, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION: 2003.....	127
Increase of HIV Cases by Region from 1999 to 2002	127
TABLE 32 INCREASE IN NUMBER OF PEOPLE NEWLY INFECTED WITH HIV, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION: 1999-2002	127
2003 AIDS Deaths by Region.....	128
TABLE 33 ESTIMATED NUMBER OF DEATHS FROM AIDS, ADULTS AND CHILDREN, BY GEOGRAPHIC REGION: 2003.....	128
Estimated Number of HIV Cases by Country in 2002 and 2010.....	128
TABLE 34 ESTIMATED NUMBER OF PEOPLE INFECTED WITH HIV IN SELECTED COUNTRIES: 2002 AND 2010	128
HIV INFECTION AND AIDS CASES IN THE U.S.	129
THE DIRE NEED FOR BETTER ACCESS TO TREATMENT	129

<i>TABLE 35 PERCENT OF PATIENTS BY GEOGRAPHIC REGION RECEIVING ANTIRETROVIRAL TREATMENT FOR HIV INFECTION</i>	130
THE IMPACT OF THE AVAILABILITY OF ANTIRETROVIRAL THERAPY.....	130
THE INTRODUCTION OF HAART.....	130
<i>TABLE 36 NUMBER OF DEATHS FROM AIDS IN THE U.S., 1988-2002</i>	131
EFFORTS TO REDUCE THE COST OF HIV DRUGS IN THE DEVELOPING WORLD	131
Boehringer Ingelheim and GlaxoSmithKline Sign Agreements.....	132
AIDS Healthcare Foundation Lawsuit	132
Government Lawsuits.....	132
Sub-Saharan Africa Generic Production Agreement ...	133
Merck Announces Reduction of the Cost of Stocrin	133
Council of Ministers Program Slow to Recruit Participants	134
EFFORTS TO MAKE GENERIC HIV DRUGS AVAILABLE IN DEVELOPING COUNTRIES.....	134
The World Trade Organization Steps in.....	135
Generic Manufacturers Make a Bold Play	135
A Strategy to Gain a Foothold in the World Market.....	136
The Bush Administration Moves to Restrict Access to Generic HIV Drugs.....	136
Clinton Foundation Negotiates Lower Drug Prices for Poor Countries.....	137
Other Struggles to Gain Access to Generic HIV Drugs	137
‘THE 3 BY 5 INITIATIVE’	138
Near-term Objectives	139
Main Plan Objectives.....	139
DRUG RESISTANCE IN HIV/AIDS	139
Definition of Antiviral Drug Resistance	140
How Resistance Develops.....	141
Locations of Mutations	142
Current Status of Resistance	142
2003 CATCH Study	142
Resistance Among HIV Cases in Europe	143
<i>TABLE 37 RESISTANCE AMONG HIV-POSITIVE PATIENTS IN EUROPE AS DETERMINED BY THE CATCH STUDY</i>	143
Conclusions	143
Acute Infection and Early Disease Research Program	144
2 nd International AIDS Society Conference	145

San Francisco Study of Pockets of Resistance	
Epidemics.....	145
Epidemic Control Recommendations	146
Types of Drug Resistance Testing.....	146
Genotypic and Phenotypic Testing.....	147
TABLE 38 <i>PROTEASE MUTATIONS</i>	147
TABLE 39 <i>REVERSE TRANSCRIPTASE MUTATIONS</i>	148
Genotypic and Phenotypic Testing	
(Continued)	149
TABLE 40 <i>ADVANTAGES AND DISADVANTAGES OF GENOTYPIC VERSUS</i>	
<i>PHENOTYPIC TESTING</i>	150
Reimbursement for HIV Drug Resistance Testing	151
Guidelines for HIV Drug Resistance Testing	151
The Special Case of Protease Inhibitors	151
The Rationale for Genotypic Testing for HIV-I Drug	
Resistance	152
Available HIV Drug Resistance Tests.....	153
NEW SALIVA TEST APPROVED TO DETECT HIV	153
COST OF HIV/AIDS TREATMENT	154
TABLE 41 <i>ESTIMATED ANNUAL COSTS FOR HAART IN U.S. AND SUB-SAHARAN</i>	
<i>AFRICA</i>	154
ABBOTT INCREASES THE COST OF NORVIR FIVE-FOLD	155
TABLE 42 <i>COMPARISON OF AVERAGE ANNUAL COST OF BOOSTED* PROTEASE</i>	
<i>INHIBITOR-BASED HIV TREATMENT REGIMENS BEFORE AND AFTER</i>	
<i>NORVIR PRICE INCREASE</i>	156
AVAILABLE PRODUCTS FOR THE TREATMENT OF HIV	
INFECTION AND AIDS	156
TABLE 43 <i>FDA-APPROVED DRUGS FOR THE TREATMENT OF HIV</i>	
<i>INFECTION/AIDS</i>	156
TABLE 43 (CONTINUED)	157
PRODUCTS FOR THE PREVENTION/TREATMENT OF	
ANTIVIRAL DISEASES INTRODUCED IN 2001, 2002 AND	
2003	158
TABLE 44 <i>ANTIVIRAL AND VACCINE PRODUCT INTRODUCTIONS, U.S.: 2001-2003</i>	158
TABLE 44 (CONTINUED)	159
TABLE 44 (CONTINUED)	160
THE MARKET FOR PRODUCTS TO TREAT HIV INFECTION	
AND AIDS	160
TABLE 45 <i>THE MARKET FOR SELECTED HIV/AIDS THERAPEUTICS:</i>	
<i>WORLDWIDE SALES, THROUGH 2009 (\$ MILLIONS)</i>	161
TABLE 46 <i>THE MARKET FOR SELECTED HIV/AIDS THERAPEUTICS BY</i>	
<i>PRODUCT CATEGORY: WORLDWIDE SALES, THROUGH 2009 (\$ MILLIONS)</i>	162
FIGURE 3 <i>THE MARKET FOR SELECTED HIV/AIDS THERAPEUTICS BY</i>	
<i>PRODUCT CATEGORY: WORLDWIDE SALES, 2001-2009 (\$ MILLIONS)</i>	162

<i>FIGURE 4 MARKET SHARE OF HIV/AIDS DRUGS BY PRODUCT CATEGORY, WORLDWIDE SALES, 2003 AND 2009 (\$ MILLIONS)</i>	163
THE U.S. MARKET FOR HIV/AIDS DRUGS	163
<i>TABLE 47 THE MARKET FOR SELECTED HIV THERAPEUTICS: U.S. SALES, THROUGH 2009 (\$ MILLIONS)</i>	164
COMBINATION PRODUCTS EMERGE AS PREFERRED TREATMENT.....	164
LEADING MARKETERS OF HIV/AIDS DRUGS	165
Leaders in the Nucleoside Reverse Transcriptase Inhibitor Class.....	165
CATEGORIES OF DRUGS AVAILABLE FOR THE TREATMENT OF HIV/AIDS	165
Entry Inhibitors, Fusion Inhibitors and Receptor Inhibitors	165
Entry Inhibitors, Fusion Inhibitors and Receptor Inhibitors (Continued).....	166
Immunotherapies	167
Nonnucleoside Reverse Transcriptase Inhibitors	167
Nucleoside Reverse Transcriptase Inhibitors	167
Nucleotide Reverse Transcriptase Inhibitors.....	167
Protease Inhibitors	168
SELECTED HIV/AIDS DRUGS INTRODUCED TO THE U.S. MARKET IN 2001, 2002 AND 2003.....	168
Fusion Inhibitors	169
Nonnucleoside Reverse Transcriptase Inhibitors	170
Sustiva.....	170
Nucleoside Reverse Transcriptase Inhibitors	171
Emtriva	172
Nucleotide Reverse Transcriptase Inhibitors.....	172
Protease Inhibitors	173
Lexiva/Telzir	173
Reyataz.....	173
Reyataz (Continued)	174
Kaletra.....	175
<i>TABLE 48 PROTEASE INHIBITOR PRESCRIPTION MARKET SHARE, BY PRODUCT, JUNE 1, 2003 TO NOVEMBER 30, 2003: U.S.</i>	175
DOSING AND COMPLIANCE CHALLENGES.....	175
<i>TABLE 49 DAILY DOSAGE REQUIREMENTS FOR SELECTED HIV/AIDS THERAPIES</i>	176
<i>TABLE 50 RELATIONSHIP BETWEEN COMPLIANCE AND DOSING FREQUENCY</i>	176
THE IDEAL TREATMENT REGIMEN	176
THE NUMBER OF SALVAGE PATIENTS CONTINUES TO INCREASE.....	177

DRUGS IN DEVELOPMENT FOR THE TREATMENT AND/OR PREVENTION OF HIV INFECTION AND AIDS	178
<i>TABLE 51 PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT AND/OR PREVENTION OF HIV INFECTION/AIDS</i>	<i>178</i>
<i>TABLE 51 (CONTINUED)</i>	<i>179</i>
THE FOUR MAIN TARGETS FOR ANTIRETROVIRAL DRUGS	179
Entry Mechanisms.....	180
Integrase	180
Protease.....	180
Reverse Transcriptase.....	180
ANTIVIRAL PRODUCTS PROJECTED TO BE INTRODUCED IN 2004 AND 2005.....	180
<i>TABLE 52 PROJECTED PRODUCT INTRODUCTIONS TO ADDRESS VIRAL DISEASES: 2004-2005</i>	<i>181</i>
<i>TABLE 52 (CONTINUED)</i>	<i>182</i>
C31G 1% Vaginal Gel.....	182
Capravirine	182
Remune	183
Viread/Emtriva Combination Product.....	184
OTHER PRODUCTS IN LATE-STAGE DEVELOPMENT	184
TMC-114	184
TIPRANAVIR	185
OTHER SELECTED PRODUCTS IN EARLIER DEVELOPMENT	185
CCR5 Antagonists	186
HIV-Hemopurifier	186
PRO-542	186
VGX-410.....	187
Viread.....	188
AIDS VACCINES IN DEVELOPMENT	188
Status of Selected Products.....	189
<i>TABLE 53 SELECTED HIV AND AIDS VACCINES IN DEVELOPMENT</i>	<i>189</i>
<i>TABLE 53 (CONTINUED)</i>	<i>190</i>
Class and Vector of Selected Products	190
<i>TABLE 54 VACCINE TYPE AND VECTORS FOR HIV VACCINES IN PHASE I/II TRIALS.....</i>	<i>191</i>
Development Strategies	191
Barriers	192
Vaccine Candidates and Target Market	192
Results of Early Trials with HIV/AIDS Vaccines.....	193
AIDSVAX	194
ALVAC HIV	194

Gp120 Vaccines.....	194
Gp160 Vaccines.....	194
Live Virus HIV Vaccine.....	195
OTHER EMERGING VIRAL DISEASE THREATS	196
DENGUE VIRUS	196
EBOLA VIRUS.....	197
OUTBREAK LOCALES	198
INFECTION AND TRANSMISSION.....	198
RECOVERY FACTORS	199
DIAGNOSIS	199
TREATMENT.....	199
ENTEROVIRUSES.....	199
HANTAVIRUSES	200
INFLUENZA	201
THE ALGORITHM OF THE PANDEMIC.....	202
AVIAN INFLUENZA	202
The Concern about the H5N1 Subtype.....	203
INFLUENZA TYPE A.....	204
PROGRESS MADE SINCE THE 1918-1919 PANDEMIC.....	205
DIAGNOSTIC AND THERAPEUTIC PRODUCTS FOR	
INFLUENZA	205
Flumadine	206
Relenza.....	207
Symmetrel.....	207
Tamiflu.....	208
Vaccines	208
MARBURG VIRUS	208
OUTBREAK LOCALES	208
INFECTION AND TRANSMISSION.....	209
DIAGNOSIS	210
RECOVERY FACTORS	210
TREATMENT.....	210
NIPAH VIRUS	210
OUTBREAK LOCALES	211
INFECTION AND TRANSMISSION.....	212
TREATMENT.....	212
NORWALK VIRUS	212
SEVERE ACUTE RESPIRATORY SYNDROME.....	213
VARIANT CREUTZFELDT-JAKOB DISEASE	214
INFECTION AND TRANSMISSION.....	214

MBM AND EXPORT BANS.....	215
OUTBREAK LOCALES	215
WEST NILE VIRUS.....	215
YELLOW FEVER.....	216
INFECTION AND TRANSMISSION.....	216
OUTBREAK LOCALES	217
RECOVERY FACTORS	217
DIAGNOSIS	218
TREATMENT.....	218
COMPANY PROFILES	219
AVANT IMMUNOTHERAPEUTICS, INC.	219
BUSINESS OVERVIEW.....	219
FINANCIAL INFORMATION.....	219
PRODUCTS	219
<i>TABLE 55 AVANT IMMUNOTHERAPEUTICS' PRODUCT PIPELINE</i>	<i>220</i>
CORPORATE STRATEGY	220
BIOSYNEXUS, INC.....	221
BUSINESS OVERVIEW.....	221
PRODUCTS	221
CORPORATE STRATEGY	221
BRISTOL-MYERS SQUIBB.....	222
BUSINESS OVERVIEW.....	222
FINANCIAL INFORMATION.....	222
PRODUCTS	222
CORPORATE STRATEGY	223
CHIRON CORP.....	223
BUSINESS OVERVIEW.....	223
FINANCIAL INFORMATION.....	223
PRODUCTS	224
<i>TABLE 56 SELECTED VACCINES AND BIOPHARMACEUTICALS IN CHIRON'S</i>	
<i>PRODUCT PIPELINE</i>	<i>225</i>
CORPORATE STRATEGY	225
CUBIST PHARMACEUTICALS, INC.	225
BUSINESS OVERVIEW.....	225
FINANCIAL INFORMATION.....	225
PRODUCTS	226
Products (Continued).....	227
CORPORATE STRATEGY	228
GILEAD SCIENCES, INC.....	229
BUSINESS OVERVIEW.....	229
FINANCIAL INFORMATION.....	229

PRODUCTS	229
<i>TABLE 57 GILEAD'S PRODUCT PIPELINE</i>	<i>230</i>
CORPORATE STRATEGY	230
GLAXOSMITHKLINE PLC	231
BUSINESS OVERVIEW.....	231
FINANCIAL INFORMATION.....	232
<i>TABLE 58 GLAXOSMITHKLINE'S ANTIBACTERIAL AND HIV/AIDS PRODUCT</i>	
<i>SALES, 2002 AND 2003 (\$ MILLIONS).....</i>	<i>232</i>
PRODUCTS	233
<i>TABLE 59 GLAXOSMITHKLINE'S ANTIBACTERIAL, HIV/AIDS DRUGS AND</i>	
<i>ANTIVIRAL VACCINE PRODUCT PIPELINE.....</i>	<i>233</i>
<i>TABLE 59 (CONTINUED)</i>	<i>234</i>
CORPORATE STRATEGY	234
INTERMUNE, INC.....	235
BUSINESS OVERVIEW.....	235
FINANCIAL INFORMATION.....	235
PRODUCTS	235
CORPORATE STRATEGY	235
MICROLOGIX BIOTECH INC.	236
BUSINESS OVERVIEW.....	236
FINANCIAL INFORMATION.....	236
PRODUCTS	236
Products (Continued).....	237
<i>TABLE 60 MICROLOGIX'S PRODUCT PIPELINE.....</i>	<i>238</i>
COMPANY STRATEGY.....	238
OSCIENT PHARMACEUTICALS, INC. (FORMERLY GENOME	
THERAPEUTICS CORP.)	239
BUSINESS OVERVIEW.....	239
FINANCIAL INFORMATION.....	239
PRODUCTS	240
<i>TABLE 61 OSCIENTOSCIENT PHARMACEUTICALS' PRODUCT PIPELINE.....</i>	<i>240</i>
<i>TABLE 61 (CONTINUED)</i>	<i>241</i>
CORPORATE STRATEGY	241
<i>TABLE 62 OSCIENT PHARMACEUTICALS' CORPORATE PARTNERSHIPS.....</i>	<i>242</i>
PFIZER CORP.....	242
BUSINESS OVERVIEW.....	242
FINANCIAL INFORMATION.....	243
PRODUCTS	243
CORPORATE STRATEGY	244
SALIX PHARMACEUTICALS, INC.	244
BUSINESS OVERVIEW.....	244
FINANCIAL INFORMATION.....	244
PRODUCTS	244

	CORPORATE STRATEGY	245
	VICURON, INC.....	246
	BUSINESS OVERVIEW.....	246
	FINANCIAL INFORMATION.....	246
	PRODUCTS	247
<i>TABLE 63</i>	<i>VICURON'S PRODUCT PIPELINE.....</i>	<i>247</i>
	CORPORATE STRATEGY	247
	Corporate Strategy (Continued).....	248
	Corporate Strategy (Continued).....	249
	VIROLOGIC, INC.	250
	BUSINESS OVERVIEW.....	250
	FINANCIAL INFORMATION.....	250
	PRODUCTS	250
	Products (Continued).....	251
	CORPORATE STRATEGY	252